Eli Lilly reserves $470M for new manufacturing plant — and North Carolina is more than pleased
Eli Lilly is adding an eighth site to its network of manufacturing plants in the US, investing $470 million to begin production of injectable products and delivery devices at Research Triangle Park, North Carolina.
Anchored by three of the state’s top research universities, RTP is also home to some of the world’s top contract research organizations as well as a growing group of biopharma companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.